Neuro-oncology practice最新文献

筛选
英文 中文
Cerebrospinal fluid diversion prior to posterior fossa tumor resection in adults: A systematic review. 成人后窝肿瘤切除术前的脑脊液转移:系统性综述。
IF 2.4
Neuro-oncology practice Pub Date : 2024-06-20 eCollection Date: 2024-12-01 DOI: 10.1093/nop/npae055
Amisha Vastani, Asfand Baig Mirza, Fizza Ali, Allayna Iqbal, Chaitanya Sharma, Abbas Khizar Khoja, Babar Vaqas, José Pedro Lavrador, Jonathan Pollock
{"title":"Cerebrospinal fluid diversion prior to posterior fossa tumor resection in adults: A systematic review.","authors":"Amisha Vastani, Asfand Baig Mirza, Fizza Ali, Allayna Iqbal, Chaitanya Sharma, Abbas Khizar Khoja, Babar Vaqas, José Pedro Lavrador, Jonathan Pollock","doi":"10.1093/nop/npae055","DOIUrl":"10.1093/nop/npae055","url":null,"abstract":"<p><strong>Background: </strong>Posterior fossa tumors (PFTs) comprise 15%-20% of adult brain tumors, with the reported frequency of hydrocephalus (HCP) ranging between 3.7% and 58%. Most HCP resolves after resection of PFTs, but studies report persistent or new-onset HCP occurring in between 2% and 7% of cases. Preoperative cerebrospinal fluid (CSF) diversion with a ventriculoperitoneal shunt (VPS), external ventricular drain (EVD), or endoscopic third ventriculostomy (ETV) has been shown to improve outcomes. Evidence regarding the efficacy of these techniques is limited.</p><p><strong>Methods: </strong>A systematic literature search was performed in line with Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Data points were extracted from individual patient cohort data. A failure rate was determined by the number of patients requiring further postoperative CSF diversion.</p><p><strong>Results: </strong>In total, 8863 records were identified. Thirteen studies consisting of 17 patient cohorts met our inclusion criteria. Across all individual cohort studies, 2976 patients underwent surgical resection of a PFT in whom the frequency of hydrocephalus at presentation was 22.98% (1.92%-100%), and persistent hydrocephalus following preoperative CSF diversion was 13.63% (0%-18%). Of the 684 hydrocephalic patients, 83.63% underwent CSF diversion in the form of ETV, EVD, or VPS. Between years 1992 and 2020, 1986 and 2021, and 1981and 2013, the pre-resection ETV, EVD, and VPS failure rates were 14.66% (17/116), 16.26% (60/369), and 0% (0/87), respectively.</p><p><strong>Conclusions: </strong>This systematic review highlights that VPS has a better failure rate profile in minimizing postoperative hydrocephalus in adult patients with PFTs.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"11 6","pages":"703-712"},"PeriodicalIF":2.4,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11567752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying research priorities and essential elements of palliative care services for people facing malignant brain tumors: A participatory co-design approach. 为恶性脑肿瘤患者确定研究重点和姑息关怀服务的基本要素:参与式共同设计方法。
IF 2.4
Neuro-oncology practice Pub Date : 2024-06-19 eCollection Date: 2024-10-01 DOI: 10.1093/nop/npae052
Liz Salmi, Shirley Otis-Green, Adam Hayden, Lynne P Taylor, Maija Reblin, Bethany M Kwan
{"title":"Identifying research priorities and essential elements of palliative care services for people facing malignant brain tumors: A participatory co-design approach.","authors":"Liz Salmi, Shirley Otis-Green, Adam Hayden, Lynne P Taylor, Maija Reblin, Bethany M Kwan","doi":"10.1093/nop/npae052","DOIUrl":"10.1093/nop/npae052","url":null,"abstract":"<p><strong>Background: </strong>Primary malignant brain tumors (ie, brain cancer) impact the quality of life (QoL) for patients and care partners in disease-specific ways involving cognition and communication. Palliative care (PC) addresses patient/care partner QoL, but it is not known how PC may address the unique needs of brain cancer patients. The purpose of this project was to identify brain cancer PC research priorities using participatory co-design methods.</p><p><strong>Methods: </strong>Participatory co-design included the formation of a longitudinal, collaborative advisory group, engagement frameworks, design-thinking processes, and social media-based engagement over a 1-year period. Community-identified brain cancer QoL needs and research priorities were mapped to proposed \"essential elements\" of brain cancer PC services.</p><p><strong>Results: </strong>We engaged an estimated 500 patients, care partners, healthcare professionals, and others with an interest in QoL and PC services for people with malignant brain tumors. Research priorities included testing the early introduction of PC services designed to address the unique QoL needs of brain cancer patients and care partners. Essential elements of brain cancer PC include: (1) addressing brain cancer patients' unique range of QoL needs and concerns, which change over time, (2) tailoring existing services and approaches to patient needs and concerns, (3) enhancing the involvement of interprofessional care team members, and (4) optimizing timing for PC services. This was the first participatory research effort exploring brain cancer patient and care partner QoL needs and PC services.</p><p><strong>Conclusions: </strong>The brain tumor community calls for research testing PC service models for patients that incorporate the \"essential elements\" of palliative care.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"11 5","pages":"556-565"},"PeriodicalIF":2.4,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11398937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142292227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The disparity in pediatric spinal cord tumor clinical trials: A scoping review of registered clinical trials from 1989 to 2023. 小儿脊髓肿瘤临床试验的差异:对1989年至2023年注册的临床试验进行范围审查。
IF 2.4
Neuro-oncology practice Pub Date : 2024-05-17 eCollection Date: 2024-10-01 DOI: 10.1093/nop/npae041
Obed Posada Villanueva, Joanna E Papadakis, Amanda M Mosher, Tabitha Cooney, Katie P Fehnel
{"title":"The disparity in pediatric spinal cord tumor clinical trials: A scoping review of registered clinical trials from 1989 to 2023.","authors":"Obed Posada Villanueva, Joanna E Papadakis, Amanda M Mosher, Tabitha Cooney, Katie P Fehnel","doi":"10.1093/nop/npae041","DOIUrl":"10.1093/nop/npae041","url":null,"abstract":"<p><strong>Background: </strong>Spinal cord tumors (SCTs) comprise 10% of all central nervous system (CNS) tumors. Pediatric SCTs are often excluded and underrepresented in clinical trials though exclusion rates haven't been reported.</p><p><strong>Methods: </strong>We reviewed all interventional clinical trials recruiting patients <21 years with SCTs on ClinicalTrials.gov between 1989 and 2023.</p><p><strong>Results: </strong>Five hundred and two CNS tumor trials were identified, of which 255 included SCTs and/or spincal metastases. Among these, 96.5% were open to all CNS tumors (brain or spine); however, only 3.5% were exclusive to spine tumors. One trial was specific to pediatric spine tumors (inclusive of bone, soft tissue, and neural tumors); no trial was specific to primary pediatric SCTs. Most trials were located in North America, with multisite investigations being more common than single-institution designs. Trials frequently evaluated interventions/treatments (89%), supportive care/quality of life measures (7.1%), or diagnostic protocols (3.1%). Among included treatment paradigms, systemic therapies using cytotoxic chemotherapies, targeted therapies, and/or immunotherapies were more common among brain/spine trials, while radiotherapy, surgical adjuncts, and/or local drug delivery more frequently occurred in spinal tumor trials.</p><p><strong>Conclusions: </strong>Though SCTs comprise 10% of pediatric CNS tumors, they remain underrepresented in clinical trials. This lack of trials specific to advancing pediatric SCTs management highlights an area of clinical and research need.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"11 5","pages":"532-545"},"PeriodicalIF":2.4,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11398943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142292230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Life with a lower-grade glioma: How can neuro-oncologists advance its understanding and management? 低级别胶质瘤患者的生活:神经肿瘤学家如何促进对其的理解和管理?
IF 2.4
Neuro-oncology practice Pub Date : 2024-05-10 eCollection Date: 2024-06-01 DOI: 10.1093/nop/npae031
Amélie Darlix, Estelle Guerdoux
{"title":"Life with a lower-grade glioma: How can neuro-oncologists advance its understanding and management?","authors":"Amélie Darlix, Estelle Guerdoux","doi":"10.1093/nop/npae031","DOIUrl":"10.1093/nop/npae031","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"11 3","pages":"223-225"},"PeriodicalIF":2.4,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11085829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140911289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Controversies in neuro-oncology: Focal proton versus photon radiation therapy for adult brain tumors. 神经肿瘤学的争议:成人脑肿瘤的局部质子与光子放射治疗。
IF 2.4
Neuro-oncology practice Pub Date : 2024-04-29 eCollection Date: 2024-08-01 DOI: 10.1093/nop/npae040
Danielle B P Eekers, Catharina M L Zegers, Kamran A Ahmed, Dante Amelio, Tejpal Gupta, Semi Ben Harrabi, Tomas Kazda, Daniele Scartoni, Clemens Seidel, Helen A Shih, Giuseppe Minniti
{"title":"Controversies in neuro-oncology: Focal proton versus photon radiation therapy for adult brain tumors.","authors":"Danielle B P Eekers, Catharina M L Zegers, Kamran A Ahmed, Dante Amelio, Tejpal Gupta, Semi Ben Harrabi, Tomas Kazda, Daniele Scartoni, Clemens Seidel, Helen A Shih, Giuseppe Minniti","doi":"10.1093/nop/npae040","DOIUrl":"10.1093/nop/npae040","url":null,"abstract":"<p><p>Radiation therapy (RT) plays a fundamental role in the treatment of malignant and benign brain tumors. Current state-of-the-art photon- and proton-based RT combines more conformal dose distribution of target volumes and accurate dose delivery while limiting the adverse radiation effects. PubMed was systematically searched from from 2000 to October 2023 to identify studies reporting outcomes related to treatment of central nervous system (CNS)/skull base tumors with PT in adults. Several studies have demonstrated that proton therapy (PT) provides a reduced dose to healthy brain parenchyma compared with photon-based (xRT) radiation techniques. However, whether dosimetric advantages translate into superior clinical outcomes for different adult brain tumors remains an open question. This review aims at critically reviewing the recent studies on PT in adult patients with brain tumors, including glioma, meningiomas, and chordomas, to explore its potential benefits compared with xRT.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"11 4","pages":"369-382"},"PeriodicalIF":2.4,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11241386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Establishing the minimal clinically important difference of the Brief Fatigue Inventory for brain or CNS cancer patients undergoing radiotherapy. 确定接受放疗的脑癌或中枢神经系统癌症患者的简易疲劳量表的最小临床重要差异。
IF 2.4
Neuro-oncology practice Pub Date : 2024-04-27 eCollection Date: 2024-10-01 DOI: 10.1093/nop/npae034
Heather J Gunn, Isabella Zaniletti, William G Breen, Todd Leavitt, Aaron Bogan, Anita Mahajan, Paul D Brown, Elizabeth Yan, Sujay A Vora, Kenneth W Merrell, Jonathan B Ashman, Jennifer L Peterson, James L Leenstra, Zachary C Wilson, Brady S Laughlin, Nadia N Laack, Todd A DeWees
{"title":"Establishing the minimal clinically important difference of the Brief Fatigue Inventory for brain or CNS cancer patients undergoing radiotherapy.","authors":"Heather J Gunn, Isabella Zaniletti, William G Breen, Todd Leavitt, Aaron Bogan, Anita Mahajan, Paul D Brown, Elizabeth Yan, Sujay A Vora, Kenneth W Merrell, Jonathan B Ashman, Jennifer L Peterson, James L Leenstra, Zachary C Wilson, Brady S Laughlin, Nadia N Laack, Todd A DeWees","doi":"10.1093/nop/npae034","DOIUrl":"10.1093/nop/npae034","url":null,"abstract":"<p><strong>Background: </strong>Minimal clinically important differences (MCIDs) quantify the clinical relevance of quality of life results at the individual patient and group level. The aim of this study was to estimate the MCID for the Brief Fatigue Inventory (BFI) and the Worst and Usual Fatigue items in patients with brain or CNS cancer undergoing curative radiotherapy.</p><p><strong>Methods: </strong>Data from a multi-site prospective registry was used. The MCID was calculated using distribution-based and anchor-based approaches. For the anchor-based approach, the fatigue item from the PROMIS-10 served as the anchor to determine if a patient improved, deteriorated, or had no change from baseline to end of treatment (EOT). We compared the unadjusted means on the BFI for the 3 groups to calculate the MCID. For the distribution-based approaches, we calculated the MCID as 0.5 SD of the scores and as 1.96 times the standard error of measurement.</p><p><strong>Results: </strong>Three-hundred and fifty nine patients with brain or CNS tumors undergoing curative radiotherapy filled out the 9-item BFI at baseline and EOT. The MCID for the BFI was 1.33 (ranging from 0.99 to 1.70 across the approaches), 1.51 (ranging from 1.16 to 2.02) and 1.76 (ranging from 1.38 to 2.14) for the usual and worst fatigue items, respectively.</p><p><strong>Conclusions: </strong>This study provides the MCID ranges for the BFI and Worst and Usual fatigue items, which will allow clinically meaningful conclusions to be drawn from BFI scores. These results can be used to select optimal treatments for patients with brain or CNS cancer or to interpret BFI scores from clinical trials.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"11 5","pages":"633-639"},"PeriodicalIF":2.4,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11398933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142292225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Healthcare spending versus mortality in central nervous system cancer: Has anything changed? 中枢神经系统癌症的医疗支出与死亡率:有什么变化吗?
IF 2.4
Neuro-oncology practice Pub Date : 2024-04-27 eCollection Date: 2024-10-01 DOI: 10.1093/nop/npae039
Eddie Guo, Mehul Gupta, Heather Rossong, Lyndon Boone, Branavan Manoranjan, Shubidito Ahmed, Igor Stukalin, Sanju Lama, Garnette R Sutherland
{"title":"Healthcare spending versus mortality in central nervous system cancer: Has anything changed?","authors":"Eddie Guo, Mehul Gupta, Heather Rossong, Lyndon Boone, Branavan Manoranjan, Shubidito Ahmed, Igor Stukalin, Sanju Lama, Garnette R Sutherland","doi":"10.1093/nop/npae039","DOIUrl":"10.1093/nop/npae039","url":null,"abstract":"<p><strong>Background: </strong>The financial implications of central nervous system (CNS) cancers are substantial, not only for the healthcare service and payers, but also for the patients who bear the brunt of direct, indirect, and intangible costs. This study sought to investigate the impact of healthcare spending on CNS cancer survival using recent US data.</p><p><strong>Methods: </strong>This study used public data from the Disease Expenditure Project 2016 and the Global Burden of Disease Study 2019. The primary outcome was the annual healthcare spending trend from 1996 and 2016 on CNS tumors adjusted for disease prevalence, alongside morbidity and mortality. Secondary outcomes included drivers of change in healthcare expenditures for CNS cancers. Subgroup analysis was performed stratified by age group, expenditure type, and care type provided.</p><p><strong>Results: </strong>There was a significant increase in total healthcare spending on CNS cancers from $2.72 billion (95% CI: $2.47B to $2.97B) in 1996 to $6.85 billion (95% CI: $5.98B to $7.57B) in 2016. Despite the spending increase, the mortality rate per 100 000 people increased, with 5.30 ± 0.47 in 1996 and 7.02 ± 0.47 in 2016, with an average of 5.78 ± 0.47 deaths per 100 000 over the period. The subgroups with the highest expenditure included patients aged 45 to 64, those with private insurance, and those receiving inpatient care.</p><p><strong>Conclusions: </strong>This study highlights a significant rise in healthcare costs for CNS cancers without corresponding improvements in mortality rate, indicating a mismatch of healthcare spending, contemporary advances, and patient outcomes as it relates to mortality.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"11 5","pages":"566-574"},"PeriodicalIF":2.4,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11398934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142292226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of prognostic biomarkers in meningiomas and their clinical implications in settings with limited resources. 在资源有限的情况下评估脑膜瘤的预后生物标志物及其临床意义。
IF 2.4
Neuro-oncology practice Pub Date : 2024-04-09 eCollection Date: 2024-08-01 DOI: 10.1093/nop/npae027
Jyotsna Singh, Trishala Mohan, Saumya Sahu, Mehar C Sharma, Ashish Suri, Chitra Sarkar, Vaishali Suri
{"title":"Evaluation of prognostic biomarkers in meningiomas and their clinical implications in settings with limited resources.","authors":"Jyotsna Singh, Trishala Mohan, Saumya Sahu, Mehar C Sharma, Ashish Suri, Chitra Sarkar, Vaishali Suri","doi":"10.1093/nop/npae027","DOIUrl":"10.1093/nop/npae027","url":null,"abstract":"<p><strong>Background: </strong>The 5th edition of the World Health Organization (WHO) Central Nervous System (CNS) tumor classification for meningiomas acknowledges the clinical relevance of genomic profiling studies and emphasizes the importance of incorporating molecular information alongside histopathological features, leading to more accurate diagnoses and improved patient care.</p><p><strong>Methods: </strong>We analyzed 206 meningioma samples (108 histological grade 1, 89 grade 2, and 9 grade 3) to study <i>pTERT</i> mutations, <i>CDKN2A/B</i> homozygous deletion, loss of H3K27me3, and p16 expression. The association of these molecular markers with survival outcomes was also assessed.</p><p><strong>Results: </strong><i>pTERT</i> mutation was found in 4.85% of cases, predominantly occurring in histological grade 2 (11.24%), while none of the histological grade 1 or 3 meningiomas exhibited this mutation. <i>CDKN2A/B</i> gene deletion was absent in grade 1 and detected in 2.24% of grade2, and 33.3% of histological grade 3 cases. There was a significant increase in loss of H3K27me3 with higher tumor grades, while p16 loss was observed in over 50% of cases across all histological grades. The presence of <i>pTERT</i> mutation and <i>CDKN2A/B</i> homozygous deletion resulted in the reclassification of 5.33% (11/206) of meningiomas as integrated grade 3. <i>pTERT</i> mutation and <i>CDKN2A/B</i> deletion, emerged as prognostically relevant markers, showing significant differences in progression-free survival (PFS) between integrated grade 3 and histological grade 2 meningiomas (<i>P</i> = .0002).</p><p><strong>Conclusions: </strong><i>pTERT</i> mutations are the most clinically relevant genetic alterations in meningiomas. Routine testing for <i>pTERT</i> mutations can identify high-risk cases of histologically grade 2 meningiomas, providing crucial prognostic information for treatment planning. <i>CDKN2A/B</i> alteration is rare and not cost-effective in assessing meningiomas. Immunohistochemical assessment of p16 and H3K27me3 expression lacks significant prognostic value. Assessment of <i>pTERT</i> mutations offers a cost-effective and valuable diagnostic tool for meningiomas.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"11 4","pages":"464-474"},"PeriodicalIF":2.4,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11241373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A longer and/or better life for the oldest old with glioblastoma. 让患有胶质母细胞瘤的耄耋老人活得更长和/或更好。
IF 2.4
Neuro-oncology practice Pub Date : 2024-01-29 eCollection Date: 2024-04-01 DOI: 10.1093/nop/npae007
Katrina Roberto, James R Perry
{"title":"A longer and/or better life for the oldest old with glioblastoma.","authors":"Katrina Roberto, James R Perry","doi":"10.1093/nop/npae007","DOIUrl":"10.1093/nop/npae007","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"11 2","pages":"113-114"},"PeriodicalIF":2.4,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10940815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140143915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strategies for meaningful patient and public involvement in neuro-oncological research. 让患者和公众切实参与神经肿瘤研究的策略。
IF 2.4
Neuro-oncology practice Pub Date : 2024-01-03 eCollection Date: 2024-04-01 DOI: 10.1093/nop/npad080
Karin Piil, Kresten Bundgaard Johannessen, Helle Pappot
{"title":"Strategies for meaningful patient and public involvement in neuro-oncological research.","authors":"Karin Piil, Kresten Bundgaard Johannessen, Helle Pappot","doi":"10.1093/nop/npad080","DOIUrl":"10.1093/nop/npad080","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"11 2","pages":"109-110"},"PeriodicalIF":2.4,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10940832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140143917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信